In this study we investigated the role of AIP, an index of atherogenic and cardiovascular risk, in the context of liver steatosis, finding that it could be considered a robust biomarker for identifying and stratifying patients at risk of MASLD and its associated metabolic complications, particularly when severe liver steatosis is present. Here, AIP is linked to Hepatic steatosis.